This educational program is intended for oncologists, nurses, pharmacists, and other healthcare professionals who care for patients with breast cancer.
Upon completion of this activity, participants should be able to:
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Denise A. Yardley, MD
Breast Cancer Research Program
The Sarah Cannon Research Institute and Tennessee Oncology
Denise A. Yardley, MD: researcher: AbbVie, Amgen, Biomarin, Biothera, Clovis, Incyte, Innocine, Lilly, MacroGenics, MedImmune, Medivation, Merck, Merrimack, Nektar, Novartis, Pfizer, Polyphor, Roche/Genentech, Tesaro; consultant/advisor: Athenex, bioTheranostics, G1 Therapeutics, Immunomedics, Lilly, Merck, Novartis, Pfizer, Sanofi Aventis.
Marie N. Becker, PhD
Marie N. Becker, PhD, has no relevant financial relationships to disclose.
Megan Cartwright, PhD
Senior Clinical Editor
Megan Cartwright, PhD, has no relevant financial relationships to disclose.
Kayla Douglas, PharmD
Director of Pharmacy
Mississippi Center for Advanced Medicine
Kristi Kay Orbaugh, MSN, NP, AOCNP: speaker: AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Gilead Sciences, Lilly, MorphoSys, Pfizer, Regeneron, Sanofi.
Jason J. Everly, PharmD
Jason Everly, PharmD, has no relevant financial relationships to disclose.
Associate Managing Editor
Krista Marcello has no relevant financial relationships to disclose.
Kristen Morrow, PhD
Kristen Morrow, PhD, has no relevant financial relationships to disclose.
Product Director, Hematology/Oncology
Clinical Care Options, LLC
Jim Mortimer has no relevant financial relationships to disclose.
Kevin Obholz, PhD
Editorial Director, Hematology/Oncology
Kevin Obholz, PhD, has no relevant financial relationships to disclose.
Timothy A. Quill, PhD
Senior Managing Editor
Timothy Quill, PhD, has no relevant financial relationships to disclose.
Director, CME Program Development
June Wasserstrom has no relevant financial relationships to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.
CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-225-H01-P.
Type of Activity: Knowledge
Upon successfully completing the post-test with a score of 50% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 15, 2022, through September 14, 2023:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
This program has been made available online.
The goal of this activity is to educate oncologists, oncology nurses, pharmacists, and other healthcare professionals about recent developments in the treatment of patients with early breast cancer in order to optimally individualize therapy and improve outcomes.